Synergy Pharmaceuticals Is Very Undervalued - Bret Jensen's Idea Of The Month
Summary
- We have extended our partnership with Cheddar TV to produce a Seeking Alpha 'Idea of the Month' segment.
- SA Marketplace author Bret Jensen continues the series with his idea of the month: Synergy Pharmaceuticals.
- Synergy has a unique, best-in-class drug in the GI space that has a couple advantages over market leader Linzess.
This article was written by
Finding tomorrow's big winners in the lucrative biotech sector, The Biotech Forum focuses on proprietary, breaking research on promising biotech and biopharma stocks with significant potential for outsized alpha. It is the fourth most subscribed to investment service offered through the Marketplace on SeekingAlpha.com. Our service offers a model-20 stock portfolio as well as the most active Live Chat on the Marketplace. This is where scores of seasoned biotech investors trade news and investment ideas back and forth throughout the trading day.
• • •
Specializing in profiling high beta sectors, Bret Jensen founded and also manages The Biotech Forum, The Insiders Forum, and the Busted IPO Forum model portfolios. Finding “gems” in the biotech and small-cap stock sectors, these highly volatile spaces proven hugely successful have empowered Bret Jensen's own investing portfolio.
• • •
Learn more about Bret Jensen's Marketplace Offerings: